Dyadic International, Inc.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, develops and commercializes animal-free recombinant proteins and enzymes for life sciences, food and nutrition, and bio-industrial markets. Its proprietary microbial production platforms, Dapibus™ and C1, are used to produce… From the company’s description.
Over the twelve months to Jun 30, 2026, Dyadic International, Inc. reported revenue of $3.80M, down 8.0% from a year earlier, and a net loss of $7.62M. Its operating margin was −195.1%, and operations used $7.40M in cash. In fiscal 2025, it reported revenue of $3.09M, down 11.6% from fiscal 2024, and a net loss of $7.36M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Dyadic International, Inc. does
In the company’s own words
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, develops and commercializes animal-free recombinant proteins and enzymes for life sciences, food and nutrition, and bio-industrial markets. Its proprietary microbial production platforms, Dapibus™ and C1, are used to produce products for research, diagnostics, cell culture, food ingredients, and industrial biotechnology. Commercial offerings and programs include recombinant albumin, transferrin, fibroblast growth factor, DNase I, dairy proteins, food-processing enzymes, and EN3ZYME™ for biomass conversion. Dyadic sells directly and works with distributors, manufacturers, and technology licensees; collaborations may involve development funding, product supply, royalties, or revenue sharing. Its C1 platform also supports partner programs developing vaccines, antibodies, and other biopharmaceutical products. The company sold certain industrial technology assets to Danisco USA in 2015, retaining specified C1 rights for pharmaceutical applications, and adopted its current business name in August 2025. Dyadic had five full-time employees as of December 31, 2025. Its website is www.dyadic.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- JUPITER, FL
- Fiscal year end
- December
- CIK
- 1213809
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Dyadic International, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Dyadic International, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Dyadic International, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Dyadic International, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Dyadic International, Inc.'s last four quarterly filings that the numbers alone won't show?”